Dear Administrator Brooks-LaSure,
As members of the Heart Valve Disease Policy Task Force, a national group of 30 leaders including clinician and patient advocates, we appreciate the opportunity to comment on the proposed decision memo for national coverage for Transcatheter Tricuspid Valve Replacement (TTVR). In particular, we wish to emphasize the critical importance of establishing a comprehensive Medicare coverage policy that includes all FDA-approved minimally invasive transcatheter devices to improve quality of life and functional status in patients with symptomatic severe tricuspid regurgitation (TR) despite optimal medical therapy. Such a policy is not only pivotal in addressing the unmet needs of Medicare beneficiaries suffering from tricuspid regurgitation but also in facilitating timely access to innovative and life-saving technologies.
Read full comment letter here.
